Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

FDA approves Sun Pharma’s oral JAK inhibitor Leqselvi to treat severe alopecia areata

The autoimmune disease currently affects around 700,000 people in the US

- PMLiVE

LEO Pharma receives CHMP recommendation for Anzupgo in chronic hand eczema

About 70% of patients with severe cases of the skin condition report problems performing everyday activities

- PMLiVE

AstraZeneca’s Calquence combination shows promise in chronic lymphocytic leukaemia

Approximately 4,000 new cases of the disease are diagnosed in the UK every year

- PMLiVE

Johnson & Johnson’s Yuvanci recommended by CHMP to treat pulmonary arterial hypertension

The rare form of pulmonary hypertension affects around 30,000 people in the EU

- PMLiVE

Start SMART

Collecting the right data in the right way for the right reasons

Group of friends smiling together

Empowering patients through more accessible clinical trial information

Senior Medical Writer, Scott Palmer explores the challenges and solutions in enhancing patient engagement in clinical trials, from the pivotal role of healthcare professionals, to the importance of user-friendly trial...

Cuttsy + Cuttsy

- PMLiVE

PLANNING SOCIAL MEDIA CAMPAIGNS – THE HEALTHCARE MARKETER’S GUIDE

Social media channels are now a key part of how brands and audiences connect and communicate. Audiences are no longer passive recipients to brand messaging; two-way communication is an expectation...

IGNIFI

- PMLiVE

Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine approved by MHRA

The UK regulator has approved four versions of the updated vaccine for adults and children from infancy

- PMLiVE

Merck’s Keytruda combination recommended by NICE for advanced gastric cancer

More than 6,500 new cases of gastric cancer are diagnosed in the UK every year

- PMLiVE

Study reveals GSK’s new recombinant shingles vaccine could reduce dementia risk

Shingrix reduced dementia diagnoses by 17% compared to Merck & Co’s Zostavax after six years

- PMLiVE

Johnson & Johnson’s Rybrevant recommended by CHMP for pre-treated advanced NSCLC

Non-small lung cancer accounts for up to 85% of all lung cancer cases

- PMLiVE

Creativity at Cannes Lions 2024

Across almost every sector, brands are multiplying their investment in creativity

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links